The current global health emergency caused by the SARS-CoV-2 pandemic poses an urgent need for vaccines and drugs to prevent infections and manage COVID-19. By drug repurposing, i.e. by using existing active agents with known safety profiles or drugs approved already for treating other diseases or conditions for new therapeutic purposes, Fraunhofer scientists are aiming to quickly identify drugs and develop therapies for COVID-19 treatment. This approach is used in the DRECOR project, addressing above all the following goals: First of all, the scientists want to identify suitable candidate molecules targeting the lungs and airways and formulate these for inhaled or systemic administration. For inhaled administration of these drugs, a prototype of a smart medical device for use in clinical trials will be created in addition. Furthermore, the team will set up complex in-vitro models and test systems that will also be available for use in other projects targeting different therapeutic areas. In the long run, DRECOR is aimed at establishing a multidisciplinary drug formulation and delivery network and process, so as to be better prepared for future pandemics. Seven Fraunhofer Institutes are collaborating in the DRECOR project, coordinated by Fraunhofer IME.
Project partners: Fraunhofer IME, Fraunhofer IGB, Fraunhofer ISC, Fraunhofer IBMT, Fraunhofer ITEM, Fraunhofer IAP, Fraunhofer IZI, Fraunhofer Project Center for Drug Discovery and Delivery at Hebrew University of Jerusalem (Israel)
Our contacts: Prof. Dr. Armin Braun, Dr. Gerhard Pohlmann